Related Articles
Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer
Economical data and advanced prostate carcinoma: Do we need new guidelines for decision making?
Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.
Cost‑effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
Cost‑effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor‑mutated non‑small‑cell lung cancer